OSE Immunotherapeutics announced today that it has received non-dilutive funding of €1.5 million from Bpifrance - Direction Régionale de Nantes.

This funding is aimed at accelerating the development of an innovative companion diagnostic test based on a simple blood sample.

It should enable the identification of HLA-A2 positive non-small cell lung cancer (NSCLC) patients eligible for treatment with Tedopi® (OSE Immuno's NSCLC vaccine) in the upcoming pivotal Phase 3 clinical trial.

The aim of this final stage of clinical development is to confirm the efficacy and safety of Tedopi® in second-line treatment after failure of checkpoint inhibitors (CPIs) in HLA-A2 positive NSCLC patients.


Copyright (c) 2023 CercleFinance.com. All rights reserved.